COURAGE Follow-up Keeps Early PCI from Rewriting Stable CAD Care
More than two decades after the original COURAGE trial, the long view still does not favor routine stenting at the start of treatment for stable coronary artery disease. In an extended follow-up of veterans treated at VA hospitals, upfront percutaneous coronary intervention added to optimal medical therapy did not lower the combined risk of death or myocardial infarction compared with medical therapy alone over as long as 25 years.
The analysis followed 959 veterans from 15 Department of Veterans Affairs hospitals for a median of 15 years, with estimated 25-year outcomes extending the trial’s clinical horizon far beyond its original readouts. The estimated 25-year rate of death or heart attack was 93.3% in the PCI group and 91% in the medical therapy group, a difference that was not statistically significant. Those curves never separated in a way that suggested durable prognostic benefit from opening stable lesions early.
One sentence captures the trial’s message plainly: stenting early did not translate into longer life or fewer heart attacks.
Long-Term Event Curves Stayed Flat Between Strategies
The biology of stable coronary disease helps explain why the procedural advantage faded. PCI relieves focal stenosis and can improve ischemic symptoms, but it does not reverse the diffuse atherosclerotic process that drives future plaque rupture, thrombosis, and progressive vascular injury. In patients whose coronary disease is clinically stable, aggressive risk-factor treatment with antiplatelet therapy, statins, blood pressure control, diabetes management, and lifestyle modification may exert a broader effect on future events than a single mechanical intervention.
The post hoc follow-up also found that more than half of veterans in each treatment strategy eventually underwent revascularization at some point during follow-up. That crossover is clinically important. Patients randomized to medical therapy were not locked out of procedures forever, and many still reached the catheterization lab later as symptoms or anatomy evolved. The finding makes the absence of a long-term difference even harder to dismiss as a simple artifact of under-treatment in the conservative arm.
Earlier COURAGE results had already shown no major advantage for initial PCI, and this extended analysis reinforces that same clinical pattern from a much longer distance. For stable disease, the choice of when to intervene appears less consequential for survival than the overall intensity and durability of medical therapy.
Why the Procedure Still Has a Role at the Bedside
The study does not argue against PCI in every patient with stable coronary disease. It argues against assuming that opening a lesion early will change hard outcomes in a stable population. For many patients, the real benefit of PCI remains symptom relief when angina persists despite optimized anti-ischemic therapy, or when anatomy and ischemic burden justify a more invasive approach.
Because atherosclerosis is systemic, a focal stent does not eliminate the underlying vascular milieu. Endothelial dysfunction, lipid accumulation, inflammation, and plaque instability continue outside the treated segment, which is why a patient can undergo apparently successful revascularization and still face subsequent cardiovascular risk. That is the core reason a mechanical fix may feel definitive in the cath lab but fail to alter decades of mortality data.
The extended follow-up also speaks to the limits of using short-term procedural success as a proxy for long-term gain. Relief of ischemia, restoration of flow, and a technically successful angiogram are not the same as fewer deaths or infarctions over 25 years. Stable coronary disease remains a chronic systemic disorder, not a lesion problem alone.
Veteran Medicare Advantage Plans Shifted Cardiac Spending
A separate study in veterans enrolled in Medicare Advantage adds a financial layer to the same broader question of where cardiovascular care gets paid for. In plans where at least 20% of members were veterans, Medicare Advantage plans paid for 43.2% of cardiovascular hospitalizations, compared with 69.2% among veterans in other MA plans.
The VA paid for community hospital care in 28.1% of cases and treated patients in its own hospitals in 28.7% of cases in those veteran-heavy plans. In other MA plans, those figures were 16% and 14.8%, respectively. The cross-sectional analysis used 2021 data and cannot establish cause, but the pattern raises a sharp policy concern: some MA arrangements may be shifting cardiovascular costs away from the private plan and toward the VA system.
For clinicians, the numbers matter because they reflect how fragmented cardiovascular financing can complicate continuity of care. A veteran admitted with chest pain, heart failure, or another cardiovascular event may move through multiple payers and systems, each with different rules, networks, and administrative pathways. In practical terms, the payer structure can shape where care happens, even when the clinical need is the same.
County Veterans Services May Be an Underused Clinical Resource
The Veterans Day campaign described alongside these studies is not a clinical trial, but it points to a useful real-world support pathway. Counties in 29 states run locally funded veterans service offices that provide accredited help with federal, state, and local benefits. Those offices can matter when veterans are trying to navigate disability claims, health coverage questions, and referrals tied to service-related needs.
County-led Operation Green Light for Veterans, now in its sixth year, has encouraged counties, parishes, and boroughs to light buildings and landmarks green from Nov. 4 through Veterans Day. The symbolic gesture is simple. The access point behind it is more concrete: a local office that may help a veteran reach benefits already earned.
For physicians caring for former service members, that kind of resource can be clinically relevant when social, financial, or bureaucratic barriers interfere with follow-up. Veterans with heart disease often need more than a prescription refill or a discharge summary. They may need help connecting the dots between service, benefits, and the care system that can actually deliver the next test, procedure, or medication.
The COURAGE follow-up leaves one central question answered and another open. Routine early PCI did not improve 25-year death or myocardial infarction rates in stable coronary disease. What still needs careful bedside judgment is which symptomatic patients should still move to revascularization, and how best to keep long-term medical therapy from slipping once the procedure is off the table.